Cellectricon Launches Neurotoxicity Testing Services

Cellectricon, a neuroscience drug discovery services provider, launched its new Neurotoxicity Testing Services, expanding its discovery platform to support the early safety assessment of drug candidates. With growing interest and feedback from the neuroscience community, the new service aims to enable drug developers to detect potential neurotoxic effects sooner, helping to reduce risk, save time, and improve confidence in candidate selection.

The new testing services draw on Cellectricon’s neuroscience expertise and portfolio of validated in vitro models. Assays integrate optical electrophysiology, high-content imaging, and microfluidic systems. The result is an ability to evaluate a broad range of acute and chronic neurotoxicity endpoints, including neuronal excitability, neurite outgrowth, metabolic activity, cytokine release, and cellular phenotype. 

“In recent years, we’ve seen growing demand for early-stage neurotoxicity testing—particularly from teams developing oligonucleotide-based drugs, who often face challenges in obtaining reliable, accurate assessments,” said Mattias Karlsson, Chief Executive Officer at Cellectricon. “We recognized that our existing validated assays were exceptionally well suited to address these needs. By building on our trusted assays and in vitro models, we’re proud to offer a robust solution that helps our clients make safer, faster decisions with greater confidence.”